



PRESS RELEASE, April 15, 2020

## **New studies in animal models reveal that SelectImmune’s immunotherapy is also effective against antibiotic-resistant bacteria**

The significance of the immune system for the body’s defense has rarely been so apparent as it is now. A well-balanced immune response protects against bacteria and viruses and reduces the risk of disease. At the same time, it has become clear to all that immunity can be both a friend and an enemy. An excessive immune response that runs riot can be deadly because the body’s innate immune balance is disrupted.

SelectImmune is developing new candidate drugs that strengthen the protective immunity and combat the destructive features of the immune system. We have identified molecular mechanisms that regulate the size and quality of the immune response and specific tools to assess their effects.

New results from animal studies have revealed that immunotherapy not only reduces harmful inflammation, but it also increases the killing of bacteria in the infected tissue. Bacteria levels were reduced more rapidly in animals treated with immunotherapy than in untreated control groups. The effect is comparable with what is observed in treatments with antibiotics.

We have now shown that even antibiotic-resistant bacteria are susceptible to this new treatment. The bacteria are cleared from the tissue more quickly, in some cases within 24 hours, and the tissue returns to a healthy state within a week.

This discovery is unexpected since immunotherapy often suppresses the patient’s immune system and increases the risk of infection in, for example, cancer patients. We see significant potential to offer this more precise immunotherapy as a supplement in connection with the treatment of bacterial infections, and now also as an option when antibiotics do not work due to bacterial resistance.

*“The impact on antibiotic-resistant bacteria is incredibly important, and points to alternative treatments that are both groundbreaking and realistic,” says Catharina Svanborg, Chairman of the Board.*

**For more information, please contact:**

**Catharina Svanborg**

**Chairman of the Board, SelectImmune Pharma AB**

**Tel: +46 709 42 65 49**

E-mail: [catharina.svanborg@med.lu.se](mailto:catharina.svanborg@med.lu.se)

**Fredrik Herslow, CEO SelectImmune Pharma AB,**

**Tel: +46 70 591 15 44**

E-mail: [fredrik.herslow@selectImmune.com](mailto:fredrik.herslow@selectImmune.com)

*SelectImmune Pharma is a pharmaceutical company whose shares are traded on the Spotlight Stock Market. The company's goal is to develop new immunotherapies, which act as immune enhancers and offer alternatives to antibiotics.*